Contineum Therapeutics (CTNM) Gains from Investment Securities (2023 - 2025)
Contineum Therapeutics (CTNM) recorded quarterly Gains from Investment Securities of -$303000.0 in Q4 2025, down 105.93% quarter-over-quarter from $5.1 million in Q1 2025, and down 105.5% on a YoY basis from $5.5 million in Q4 2024.
Contineum Therapeutics (CTNM) Gains from Investment Securities (2023 - 2025) Analysis & Trends
Contineum Therapeutics' Gains from Investment Securities history runs 3 years deep, the most recent figure standing at -$303000.0 for Q4 2025.
- In Q4 2025, Gains from Investment Securities fell 105.5% year-over-year to -$303000.0; the TTM figure through Dec 2025 stood at $5.2 million (down 11.23% YoY), while the FY2025 annual figure was -$3000.0, down 100.07% from the prior year.
- Gains from Investment Securities was -$303000.0 for Q4 2025 at Contineum Therapeutics, down from $5.1 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $5.5 million in Q4 2024 to a low of -$303000.0 in Q4 2025.
- Historically, Gains from Investment Securities has averaged $2.1 million across 3 years, with a median of $400000.0 in 2023.
- The sharpest annual moves came in 2024 and 2025: Gains from Investment Securities soared 16806.06% in 2024, then plunged 105.5% in 2025.
- A 3-year view of Gains from Investment Securities shows it stood at -$33000.0 in 2023, then jumped by 16806.06% to $5.5 million in 2024, then slumped by 105.5% to -$303000.0 in 2025.
- The last three Gains from Investment Securities figures came in at -$303000.0 (Q4 2025), $5.1 million (Q1 2025), and $5.5 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Contineum Therapeutics | 423.05 Mn | 423.05 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -303,000.00 |
| Dec 31, 2025 | -303,000.00 |
| Mar 31, 2025 | 5.11 Mn |
| Mar 31, 2025 | 5.11 Mn |
| Dec 31, 2024 | 5.51 Mn |
| Dec 31, 2024 | 5.51 Mn |
| Sep 30, 2024 | 4.12 Mn |
| Sep 30, 2024 | 4.12 Mn |
| Jun 30, 2024 | -11,000.00 |
| Jun 30, 2024 | -11,000.00 |
| Dec 31, 2023 | -33,000.00 |
| Dec 31, 2023 | -33,000.00 |
| Sep 30, 2023 | 400,000.00 |
| Sep 30, 2023 | 400,000.00 |